Download the application notes
Discover how circulating immune biomarkers are enhancing cancer patient stratification and drug development.
Unveiling the blood IFN signature as a key predictor of immunotherapy resistance and clinical outcome in cancer.
Learn how cytokine profiling can reveal cytokine storm disease mechanisms, aid early prognosis, and foster personalized treatments.
Learn more about how Olink solutions can accelerate disease research and drive new therapies
See how Olink® Flex and our other inflammatory protein assays provide actionable insights across a broad range of diseases.
Olink’s highly flexible made-to-order product, Olink® Flex, enables you to select and combine targets for up to 21 human proteins in one biomarker panel.
Olink offers high-quality protein biomarker discovery based on a flexible and scalable technology platform.